Le Lézard
Classified in: Ebola virus, Health
Subject: SVY

Global Virus Like Particles Market & Clinical Trial Insights 2017-2023 - Favorable Parameters & Commercialization Challenges

DUBLIN, September 18, 2017 /PRNewswire/ --

The "Global Virus Like Particles Market & Clinical Trial Insight 2023" clinical trials has been added to Research and Markets' offering.

Research and Markets Logo

The virus like particle based vaccines is commercially available in market against the hepatitis B virus and human papillomavirus. The viruses like particle based vaccines against several other viruses are in clinical development. The under trial vaccine candidates itself represents the target antigen and those in which the virus like particle is used to present the foreign antigens to immune system. The progresses have been made in developing virus like particle vaccines against hepatitis C virus, Ebola, Lassa virus, Hantavirus and chikungunya virus. Currently there are 60 virus like particle vaccines in clinical trials and 5 virus like particle vaccines are commercially available in the market.

The major pharmaceutical companies have recognized the promising future of the virus like particle vaccines and are widely supporting the manufacturing and production of such vaccines. Major market players include some of the large scale pharmaceutical companies like GlaxoSmithKline's and Merck. The development of the cost effective vaccines are hugely supported by the governmental authorities as well as the academia and pharmaceutical companies.

The future of the virus like particle based vaccines is bright owing to the presence of multiple favorable factors and lesser challenges. The low cost and high efficiency combination will contribute as a robust of the virus like particle vaccines market. Such kind of vaccines will be easily accessible to the consumers due to the expanding market size. The future is even more optimistic in the developing countries where low price will be a favorable parameter for increased customers and demands. Overall the future of the virus like particle based vaccine is very bright and may result in replacing the whole human vaccine market by collecting high revenues for the pharmaceutical industry.

Global Virus Like Particles Market & Clinical Trial Insight 2023 report highlights:

Key Topics Covered:

1. Virus like Particles - New Generation of Vaccines
1.1 Introduction
1.2 Requirements for Virus like Particles Assembly

2. Virus Candidates for Development of Virus like Particle Vaccines
2.1 Animal Virus-like Particles as Vaccine Immunogens
2.2 Plant Virus based Virus like Particles

3. Current Advances in Virus like Particles as a Vaccination Approach against Infectious Diseases
3.1 HIV-1 Virus like Particles
3.2 Hepatitis C Virus
3.3 Malaria
3.4 Newcastle Disease
3.5 Filoviruses
3.6 Norovirus

4. Production Process of Virus like Particle based Vaccines
4.1 Expression Systems
4.2 Downstream Processing of Virus like Particle Based Vaccines

5. Market Analysis of Virus like Particles Vaccines
5.1 Introduction
5.2 Market of Virus like Particle Vaccines

6. Global Virus Like Particle Vaccines Clinical Pipeline Overview

7. Global Virus like Particle Vaccines Market Dynamics
7.1 Favorable Parameters
7.2 Commercialization Challenges

8. Future Perspective of Virus like Particles Vaccines

9. Global Virus Like Particle Vaccines Clinical Pipeline by Company, Indication & Phase
9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Phase-II/III
9.7 Phase-III

10. Marketed Virus Like Particle Vaccines Clinical Insight
10.1 Human papillomavirus vaccine recombinant quadrivalent (Gardasil & Silgard)
10.2 Human papillomavirus vaccine recombinant bivalent (Cervarix)
10.3 Human Papillomavirus Vaccine Recombinant Nonavalent (GARDASIL9)
10.4 Influenza Virus Vaccine Trivalent (CadiFlu-S)
10.5 Influenza A Virus H1N1 Vaccine (CadiFlu)

11. Competitive Landscape
11.1 Agilvax
11.2 Allergy Therapeutics
11.3 ANGANY Genetics
11.4 CPL Biologicals
11.5 Cytos Biotechnology
11.6 GeoVax Labs
11.7 GlaxoSmithKline
11.8 Medicago
11.9 MedImmune
11.10 Merck
11.11 Novavax
11.12 Serum Institute of India
11.13 Takeda
11.14 TechnoVax
11.15 Xiamen Innovax Biotech

For more information about this clinical trials report visit https://www.researchandmarkets.com/research/glmhbx/global_virus_like

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

These press releases may also interest you

14 déc 2017
Merck & Co., Inc. , known as MSD outside Canada and the United States, announced today that the recently approved PREVYMIStm (letermovir) is expected to be available in Canada by the end of December 2017. The product is indicated for the prophylaxis...

14 déc 2017
Direct Relief grew into the seventh largest charity in the United States in 2017, according to Forbes Magazine's newly released annual ranking of the 100 largest U.S. charities. The medical aid group received $1.1 billion in donations in its 2017...

8 déc 2017
Her Excellency the Right Honourable Julie Payette, Governor General of Canada, will present the Meritorious Service Decorations (Civil Division) to 42 recipients from various sectors across the country on Tuesday, December 12, 2017, at 10:30 a.m.,...

8 déc 2017
Restated segment financials As announced in April 2017, Ericsson will start to report financials according to its new segments as of the fourth quarter 2017. To facilitate year-on-year comparisons, Ericsson today discloses the restated financials...

7 déc 2017
In the search for drugs that are effective against Ebola virus, scientists from SRI International and Collaborations Pharmaceuticals, Inc., led a study that used machine learning methods to identify tilorone dihydrochloride as a potential new...

7 déc 2017
Replikins Ltd. this week reported to the Healthcare Emergency Management Program of Boston University School of Medicine a four-fold increase in gene Replikin Counts in Global MERS-CoV from 2008 to 2017 (p<0.001) ? the highest ever recorded on...

News published on 18 september 2017 at 15:15 and distributed by: